Helicobacter pylori News and Research

RSS

H pylori eradication protects against aspirin-associated peptic ulcer bleeding

A new study, led by experts at the University of Nottingham found that the risk of stomach bleeding caused by using aspirin long-term, can be reduced with a short course of antibiotics, potentially improving the safety of aspirin when used to prevent heart attacks, strokes and possibly some cancers.

4 Nov 2022

The compositional and functional diversity of the gut fungal microbiome

Researchers assessed the role of gut bacterial microbiome assembly and the gut mycobiome in relation to health, pathology, and clinical applications.

30 Sep 2022

Study finds above-average rates of mortality from gastric cancer in South Florida

South Florida counties have above-average rates of mortality from gastric cancer, according to a new study published in the journal Gastroenterology by investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

29 Jun 2022

Combination of three technologies makes potential treatment effective against aggressive brain tumor

A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers.

15 Jun 2022

Study confirms accuracy of new generation GastroPanel® test

A clinical validation study conducted at Oulu University Hospital (OUH) has confirmed the high accuracy of BIOHIT Oyj’s new generation GastroPanel® test for the diagnosis of atrophic gastritis (AG) and Helicobacter pylori (Hp) infection in patients referred for gastroscopy.

From BIOHIT HealthCare Ltd 6 May 2022

Researchers identify five types of bacteria in men with aggressive prostate cancer

Researchers at the University of East Anglia have found a link between bacteria and aggressive forms of prostate cancer.

25 Apr 2022

New study reveals oral opaganib's potent in vitro activity against Omicron

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced study results in which opaganib (ABC294640), a leading oral drug candidate for hospitalized patients with moderate to severe COVID-19, was observed to have potent in vitro efficacy against the Omicron SARS-CoV-2 variant, while maintaining host cell viability.

11 Apr 2022

Self-assembling SARS-CoV-2 spike protein-directed nanoparticle vaccines

A new preprint study depicted the generation of self-assembling coronavirus disease 2019 (COVID-19) nanoparticle vaccines.

6 Apr 2022

Phase 2/3 study of oral RHB-107 in non-hospitalized COVID-19 patients shows promising results

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced positive top-line results from the Phase 2 part of the Phase 2/3 study of once-daily oral RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients, predominantly conducted in the U.S. (60/61 patients) as well as South Africa.

1 Mar 2022

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

A new study discusses the state of current knowledge about the potential use of tea polyphenols in the prevention and treatment of COVID-19.

16 Feb 2022

Study analyzes the resistance of H. pylori bacterium to antibiotics

A UPV/EHU study analyses the resistance of the Helicobacter pylori (H. pylori) bacterium to the antibiotics routinely used to treat the infection caused by this bacterium.

29 Nov 2021

New imaging technology for detecting MALT lymphomas could save patients numerous gastroscopies

A new imaging technique for the detection of MALT lymphomas, malignant tumours of the lymphatic system, could probably save patients numerous gastroscopies. A study group of MedUni Wien achieved a high imaging accuracy by way of PET/MR and by using a PET Tracer directed against a certain cell receptor. The results are currently published in the top journal "Blood" of the American Society of Hematology.

24 Sep 2021

Researchers identify eight primary factors that increase GI bleeding risk after heart attack

Researchers at Karolinska Institutet in Sweden have identified eight primary factors that increase the risk of a common bleeding complication after heart attack. Some of these factors are already known, but using machine learning techniques, the researchers have found additional predictors, such as smoking, blood pressure and blood glucose.

23 Aug 2021

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.

20 Jul 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Irritable bowel syndrome is linked to bacterial biofilms in the gut

One in six women and one in twelve men in Austria suffers from some form of IBS - therefore around one million people in all. Using currently available techniques, it is only possible to diagnose IBS by a process of elimination.

21 Jun 2021

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva, ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).

7 Jun 2021

A SARS-CoV-2 ferritin nanoparticle vaccine elicits broad immunity

In a recent bioRxiv* preprint research paper, M. Gordon Joyce et al. designed engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of prefusion Spike (S), S1 and receptor-binding domain (RBD). They demonstrated that these immunogens induced robust S-binding, ACE2 (angiotensin-converting enzyme)-inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2 in mice.

13 May 2021

Host protein mimicry of SARS-CoV-2 receptor binding motif

In a new study, structural bioinformatics approaches are employed to investigate the potential mimicry of the receptor-binding motif (RBM) of these three coronaviruses, finding that several proteins from both human and non-human sources were similar to each, with implications regarding the mechanism of infection and tropism of SARS-CoV-2.

29 Apr 2021

Cholestenone could be a new antibacterial drug against H. pylori

Helicobacter pylori (H. pylori), a gram-negative pathogen that has infected half of the world's population is a Group I carcinogen according to the WHO. H. pylori resides in the gastric mucosa causing gastritis, ulcers, gastric cancers and malignant lymphoma of the stomach.

27 Apr 2021